A Patient-Friendly Look at the Latest Evidence
“Just give me something that works—and doesn’t make me feel worse.”
That’s the quiet hope so many of us carry into every doctor visit. If you live with neuropathic pain like I do, you know the drill: try a new prescription, wait it out, cope with side effects, maybe feel a bit of relief, maybe not.
Now, a major update from The Lancet Neurology gives us a clearer picture of what actually works for neuropathic pain—and what might not be worth the trouble.
This 2025 report reviewed 313 clinical trials involving nearly 49,000 adults. The results are both sobering and empowering.
Let’s walk through it in plain language.
First-Line Treatments: The Starting Place
These are the treatments with the best combination of effectiveness and tolerability. They’re the ones the experts say to try first.
- Tricyclic Antidepressants (TCAs) – like amitriptyline
Helped about 1 in 5 people
About 1 in 17 stopped due to side effects
→ Older drugs, low cost, moderate benefit - SNRIs – like duloxetine or venlafaxine
Helped 1 in 7
Side effects made 1 in 14 quit
→ Often used for depression and anxiety too - α2δ-Ligands – gabapentin and pregabalin
Helped 1 in 9
Side effects led to stopping in 1 in 26
→ Heavily prescribed, some swear by them, others can’t tolerate them
Second-Line Options: Try If First-Line Fails
These may help, but the effect is smaller or less certain. Still, they have low risk of harm for most people.
- Capsaicin 8% Patches
Helped 1 in 13
Very low side effect risk - Capsaicin Cream
Helped 1 in 6
Some evidence, but not strong - Lidocaine 5% Patches
Helped only a few
Very safe, but limited benefit
Third-Line Treatments: Use With Caution
These are fallback options. They might help, but come with more risks or more uncertainty.
- Botulinum Toxin (Botox)
Helped 1 in 3, which is pretty good
Very few side effects reported
Access and cost can be barriers - Repetitive Transcranial Magnetic Stimulation (rTMS)
Non-invasive brain stimulation
Still early days—needs more research - Opioids (including tramadol)
Helped 1 in 6, but with real risks
Addiction, sedation, tolerance—use only when truly needed
What This Means for You
This study confirms what many of us already feel: there’s no one-size-fits-all solution. Relief is possible, but it often takes trial and error. Even the most effective options only help a fraction of people—and that’s okay.
So how do we move forward?
- Start with first-line options
Ask your provider about TCAs, SNRIs, or gabapentin/pregabalin
Consider side effects, your other conditions, and how treatments make you feel - If those don’t work, try second-line treatments
Patches and creams might seem minor—but sometimes, small relief makes a big difference - Be cautious but open-minded about third-line choices
And always ask: Is the benefit worth the cost—physically, emotionally, financially? - Bring your voice into the decision
These recommendations were shaped with input from people with lived experience. That matters. So does what you think.
Final Thoughts
Neuropathic pain is complex. And as this review shows, even our best treatments are just the beginning. But the fact that this work involved both clinicians and patients is encouraging. We are not passive recipients of care—we are partners in making it better.
As always, keep asking questions. Keep sharing your story. Keep pushing for care that sees you as a whole person, not just a diagnosis.
You are not alone.
SOURCE:
Soliman N et al. (2025). Pharmacotherapy and Non-Invasive Neuromodulation for Neuropathic Pain: A Systematic Review and Meta-Analysis. The Lancet Neurology, Vol 24, pp. 413–428.
Read the full article here: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00068-7/fulltext
Disclaimer:
The views, positions, and recommendations expressed in this article are based on my personal experiences and independent research. They are solely my own and do not necessarily reflect the views, policies, or positions of the American Chronic Pain Association (ACPA).
Note on Tools Used:
This article was developed with the assistance of ChatGPT, guided by my lived experience with chronic pain.